
<b>Tildrakizumab</b>, an interleukin-23 inhibitor, delivers sustained clinical and patient-reported improvements for individuals suffering from moderate-to-severe plaque psoriasis after initial anti-IL-17 treatment failure, according to real-world medical data. A recent study evaluating thirty patients showed that mean Psoriasis Area and Severity Index scores dropped significantly from 12.2 to 1.1 after 52 weeks. Over eighty percent of patients achieved major skin clearance, while overall quality of life and <b>treatment satisfaction</b> improved substantially despite frequent dosage escalations to two hundred milligrams during the follow-up period.
This page is a shareable card. Download our app to get the full swipe experience!